NEW YORK, Feb. 18, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Immunomedics, Inc. IMMU
Class Period: February 8, 2018 - January 18, 2019
Lead Plaintiff Deadline: February 25, 2019
Join the action: https://www.zlk.com/pslra-1/immunomedics-inc-loss-form?wire=3
About the lawsuit: During the class period, Immunomedics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Immunomedics' Morris Plains, New Jersey drug substance manufacturing facility was not in compliance with FDA requirements; (ii) the Company's Quality Control Unit did not possess the authority to investigate and correct critical FDA violations occurring at the Morris Plains, New Jersey facility; (iii) the Company suffered a February 2018 data integrity breach at the Morris Plains, New Jersey facility which, among other issues, included the backdating records and manipulation of bioburden samples; (iv) the Company's Chemistry, Manufacturing and Control data submitted in connection with its BLA for sacituzumab govitecan was insufficient to support FDA approval; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times
To learn more about the Immunomedics, Inc. class action contact jlevi@levikorsinsky.com.
DBV Technologies S.A. DBVT
Class Period: February 14, 2018 - December 19, 2018
Lead Plaintiff Deadline: March 18, 2019
Join the action: https://www.zlk.com/pslra-1/dbv-technologies-s-a-loss-form?wire=3
About the lawsuit: DBV Technologies S.A. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) DBV Technologies' Biologics License Application ("BLA") for Viaskin Peanut failed to provide the FDA with sufficient data on manufacturing procedures and quality controls; (2) consequently, DBV Technologies voluntarily withdrew the BLA for Viaskin Peanut; and (3) as a result, defendants' statements about DBV Technologies' business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the DBV Technologies S.A. class action contact jlevi@levikorsinsky.com.
Activision Blizzard, Inc. ATVI
Class Period: August 2, 2018 - January 10, 2019
Lead Plaintiff Deadline: March 19, 2019
Join the action: https://www.zlk.com/pslra-1/activision-blizzard-inc-loss-form?wire=3
About the lawsuit: During the class period, Activision Blizzard, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the termination of Activision Blizzard and Bungie's partnership, giving Bungie full publishing rights and responsibilities for the Destiny franchise, was imminent; (ii) the termination of the two companies' relationship would foreseeably have a significant negative impact on Activision Blizzard's revenues; and (iii) as a result, Activision Blizzard's public statements were materially false and misleading at all relevant times.
To learn more about the Activision Blizzard, Inc. class action contact jlevi@levikorsinsky.com.
Molson Coors Brewing Company TAP
Class Period: February 14, 2017 - February 11, 2019
Lead Plaintiff Deadline: April 16, 2019
Join the action: https://www.zlk.com/pslra-1/molson-coors-brewing-company-loss-form?wire=3
About the lawsuit: Throughout the class period, Molson Coors Brewing Company allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Molson Coors failed to properly reconcile the outside basis deferred income tax liability for Molson Coors' investment in its MillerCoors, LLC partnership; (2) consequently, Molson Coors misreported net income in its consolidated financial statements for the fiscal years ending December 31, 2016 and December 31, 2017, resulting in an overall downward revision to net income; (3) Molson Coors lacked adequate internal controls over financial reporting; and (4) as a result, defendants' statements about Molson Coors' business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the Molson Coors Brewing Company class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
